دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study
Grace Chen, PhD, Trevor Lissoos, MD, Christopher Dieyi, MPH, Kyle D Null, PharmD, PhD
doi : 10.1093/ibd/izaa263
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1177–1183
Clinical indices to characterize the severity of inflammatory bowel disease (IBD) are widely used in clinical trials and real-world practice. However, there are few validated instruments for assessing IBD severity in administrative claims-based studies.
Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease
Montserrat Baldan-Martin, PhD, Mar?a Chaparro, MD, PhD, Javier P Gisbert, MD, PhD
doi : 10.1093/ibd/izaa352
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1184–1200
Inflammatory bowel disease (IBD) has become a global disease encompassing a group of progressive disorders characterized by recurrent chronic inflammation of the gut with variable disease courses and complications. Despite recent advances in the knowledge of IBD pathophysiology, the elucidation of its etiopathology and progression is far from fully understood, requiring complex and multiple approaches. Therefore, limited clinical progress in diagnosis, assessment of disease activity, and optimal therapeutic regimens have been made over the past few decades. This review explores recent advances and challenges in tissue proteomics with an emphasis on biomarker discovery and better understanding of the molecular mechanisms underlying IBD pathogenesis. Future multi-omic studies are required for the comprehensive molecular characterization of disease biology in real time with a future impact on early detection, disease monitoring, and prediction of the clinical outcome.
The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies
David T Rubin, MD, Jenny Griffith, PharmD, Qisu Zhang, MPH, Zsolt Hepp, PharmD, Allison Keshishian, MPH
doi : 10.1093/ibd/izaa270
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1201–1209
Although there is evidence that anti-tumor necrosis factor (TNF) utilization earlier in the inflammatory bowel disease (IBD) course and before the onset of disease-related complications leads to improved patient outcomes, the health care costs and utilization impact have not been well defined. This study assessed differences in health care utilization and costs among patients with IBD treated with anti-TNFs.
Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease
Michael T Dolinger, MD, MBA, Elizabeth A Spencer, MD, Joanne Lai, MD, David Dunkin, MD, Marla C Dubinsky, MD
doi : 10.1093/ibd/izaa277
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1210–1214
Nontraditional combination of existing therapies is often the only option to avoid surgery in refractory inflammatory bowel disease (IBD) patients. We aim to assess the efficacy and safety of concomitant use of 2 biologic therapies or combination of biologic and tofacitinib in a refractory pediatric IBD cohort.
Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease
Jacob J Rozich, MD, Jiyu Luo, MS, Parambir S Dulai, MD, Angelina E Collins, MSN, Lysianne Pham, MSN, Brigid S Boland, MD, William J Sandborn, MD, Siddharth Singh, MD, MS
doi : 10.1093/ibd/izaa308
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1215–1223
The incidence and prevalence of inflammatory bowel diseases (IBD) in older adults are rising. There is a limited comparative assessment of risk of disease- and treatment-related complications in older patients (older than 60 years) with adult-onset (age at disease onset, 18–59 years; AO-IBD) vs elderly-onset IBD (age at disease onset, older than 60 years; EO-IBD). We compared clinical outcomes in older patients with IBD with AO-IBD vs EO-IBD.
COVID-19 Pandemic’s Effects on Disease and Psychological Outcomes of People With Inflammatory Bowel Disease in Portugal: A Preliminary Research
Inês A Trindade, PhD, Nuno B Ferreira, PhD
doi : 10.1093/ibd/izaa261
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1224–1229
No empirical research on the psychological impact of the coronavirus disease 2019 (COVID-19) pandemic on people living with IBD, a population known to typically present high levels of anxiety and depression and to be potentially vulnerable to COVID-19, has yet been conducted. This study aimed to explore the links between contextual variables related to the COVID-19 pandemic and disease and psychological outcomes.
Presence of Obstructive Symptoms and Absence of Perianal Crohn Disease Is Predictive of Surgery After Endoscopic Balloon Dilation
Barathi Sivasailam, MD, Scott Manski, MD, Alicia Wentz, Raymond K Cross, MD, MS
doi : 10.1093/ibd/izaa276
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1230–1236
Patients with Crohn disease (CD) often develop strictures that require surgery. Endoscopic balloon dilation (EBD) is an alternative treatment that can be safe and effective. The objective of this study was to assess factors associated with the need for repeat EBD and surgery after initial EBD for stricturing CD.
Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease
Dario Sorrentino, MD, FRACP, James M Gray
doi : 10.1093/ibd/izaa348
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1237–1247
Fecal lactoferrin (FL) levels may mirror drug-induced changes in inflammation in ulcerative colitis and Crohn disease in a timely way and could be used to assess loss of response (LOR) to biologics.
Double-Balloon Endoscopy in Crohn Disease: A Tertiary Referral Center Experience
Brendan P Halloran, MD, Laith H Jamil, MD, Simon K Lo, MD, Matt Reeson, BSc, Eric A Vasiliauskas, MD, Stephan Targan, MD, Andrew Ippoliti, MD, Neel K Mann, MD, MPH, Gil Y Melmed, MD, MS
doi : 10.1093/ibd/izaa287
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1248–1255
Crohn disease (CD) affects the small bowel in 80% of patients. Double balloon endoscopy (DBE) provides the potential for direct and extensive mucosal visualization with the potential for diagnostic monitoring and therapeutic intervention. This study aimed to investigate the safety and effectiveness of DBE in small-bowel CD.
Chromoendoscopy With Indigo Carmine vs Virtual Chromoendoscopy (iSCAN 1) for Neoplasia Screening in Patients With Inflammatory Bowel Disease: A Prospective Randomized Study
Oscar Gonz?lez-Bernardo, MD, Sabino Riestra, PhD, Santiago Vivas, PhD, Ruth de Francisco, MD, Isabel Pérez-Mart?nez, PhD, Andrés Casta?o-Garc?a, MD, V?ctor Jiménez-Beltr?n, MD, Valeria Rollé, MD, Patricio Su?rez, MD, Adolfo Su?rez, PhD
doi : 10.1093/ibd/izaa291
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1256–1262
The risk of colon cancer is greater in patients with inflammatory bowel disease (IBD) than in the general population. Chromoendoscopy with dye (CE) is the currently recommended method for detecting dysplasia in screening colonoscopies in IBD patients; however, the role of virtual chromoendoscopy (VC) is not yet well defined.
Vitamin D Receptor Gene Single Nucleotide Polymorphisms and Association With Vitamin D Levels and Endoscopic Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Study
Anusha Shirwaikar Thomas, MD, Zachary K Criss, II, Noah F Shroyer, PhD, Bincy P Abraham, MD
doi : 10.1093/ibd/izaa292
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1263–1269
Inflammatory bowel diseases (IBDs) comprise a heterogenous group of chronic gastrointestinal disorders that are multifactorial in etiology. Experimental in vitro and in vivo studies suggest that intestinal vitamin D receptor (VDR) signaling plays a role in modulating the immune response in IBD as a cause and/or a consequence of chronic inflammation.
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Guilherme Piovezani Ramos, MD, Christina Dimopoulos, MD, Nicholas M McDonald, MD, Laurens P Janssens, MD, Kenneth W Hung, MD, Deborah Proctor, MD, Elizabeth Ruggiero, Sunanda Kane, MD, David H Bruining, MD, William A Faubion, MD, Laura E Raffals, MD, Edward V Loftus, Jr, MD, Badr Al-Bawardy, MD
doi : 10.1093/ibd/izaa293
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1270–1276
There are limited data on how vedolizumab (VDZ) impacts extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). The aim of this study was to determine the clinical outcomes of EIMs after initiation of VDZ for patients with IBD.
Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission
Hyuk Yoon, MBBS, Sushrut Jangi, MD, Parambir S Dulai, MD, Brigid S Boland, MD, Vipul Jairath, MD, PhD, Brian G Feagan, MD, MSc, William J Sandborn, MD, Siddharth Singh, MD, MS
doi : 10.1093/ibd/izaa301
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1277–1284
Although achieving histologic remission in ulcerative colitis is established, the incremental benefit of achieving histologic remission in patients with Crohn disease (CD) treated to a target of endoscopic remission is unclear. We evaluated the risk of treatment failure in patients with CD in clinical and endoscopic remission by histologic activity status.
The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time
Ruth Ann Marrie, MD, PhD, Lesley A Graff, PhD, John D Fisk, PhD, Scott B Patten, MD, PhD, Charles N Bernstein, MD the CIHR Team in Defining the Burden and Mitigating the Impact of Psychiatric Comorbidity in Immuno-inflammatory Disease
doi : 10.1093/ibd/izaa349
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1285–1293
We aimed to examine associations between elevated symptoms of depression and anxiety and disease activity in inflammatory bowel disease (IBD). Previous findings have been inconsistent and have not accounted for variability in the courses of these conditions over time.
Predictors of Ustekinumab Failure in Crohn’s Disease After Dose Intensification
Rahul S Dalal, MD, Cheikh Njie, MD, Jenna Marcus, Sanchit Gupta, MD, Jessica R Allegretti, MD, MPH
doi : 10.1093/ibd/izaa282
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1294–1301
Many patients with Crohn’s disease (CD) who lose response to the standard ustekinumab dose interval of every 8 weeks (q8w) undergo dose intensification to q4w or q6w. However, baseline factors that predict success or failure after dose intensification are unknown. We sought to identify predictors of failure of ustekinumab after dose intensification for patients with CD.
The Use of Readily Available Longitudinal Data to Predict the Likelihood of Surgery in Crohn Disease
Ryan W Stidham, MD, MS, Yumu Liu, MS, Binu Enchakalody, MS, Tony Van, Venkataramu Krishnamurthy, MD, Grace L Su, MD, Ji Zhu, PhD, Akbar K Waljee, MD, MSc
doi : 10.1093/ibd/izab035
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1328–1334
Although imaging, endoscopy, and inflammatory biomarkers are associated with future Crohn disease (CD) outcomes, common laboratory studies may also provide prognostic opportunities. We evaluated machine learning models incorporating routinely collected laboratory studies to predict surgical outcomes in U.S. Veterans with CD.
Metabolic Alteration in Plasma and Biopsies From Patients With IBD
Maria Laura Santoru, PhD, Cristina Piras, PhD, Federica Murgia, MSc, Vera Piera Leoni, PhD, Martina Spada, MSc, Antonio Murgia, PhD, Sonia Liggi, PhD, Maria Antonia Lai, MD, Paolo Usai, MD, Pierluigi Caboni, PhD, Aldo Manzin, MD, Luigi Atzori, MD, PhD
doi : 10.1093/ibd/izab012
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1335–1345
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal tract, with periods of latency alternating with phases of exacerbation, and include 2 forms: Crohn disease (CD) and ulcerative colitis (UC). Although the etiology of IBD is still unclear, the identification and understanding of pathophysiological mechanisms underlying IBD could reveal newly targeted intestinal alterations and determine therapeutic approaches.
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice
Niels Vande Casteele, PharmD, PhD, Brian G Feagan, MD, FRCPC, Douglas C Wolf, MD, Anca Pop, MD, Mohamed Yassine, MD, Sara N Horst, MD, MPH, Timothy E Ritter, MD, William J Sandborn, MD
doi : 10.1093/ibd/izaa265
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1346–1355
Therapeutic drug monitoring (TDM) is the measurement of drug and antidrug antibody concentrations in individuals to guide treatment decisions. In patients with Crohn disease (CD), TDM, used either reactively or proactively, is emerging as a valuable tool for optimization of tumor necrosis factor (TNF) antagonist therapy. Reactive TDM is carried out in response to treatment failure, whereas proactive TDM involves the periodic monitoring of patients responding to TNF antagonist therapy to allow treatment optimization. In patients with CD, most of the available data for TDM relate to the first-to-market TNF antagonist infliximab and, to a lesser extent, to adalimumab and certolizumab pegol. Several gastroenterology associations, including the American Gastroenterology Association, have endorsed the use of reactive TDM in patients with active CD. However, fewer recommendations currently exist for the use of proactive TDM, although several new prospective randomized controlled trials evaluating proactive TDM strategies have been published. In this review, the current evidence for reactive and proactive TDM is discussed, and a proactive treatment algorithm for certolizumab pegol based on previously published threshold concentrations is proposed.
Barriers to Administering Vaccines in Inflammatory Bowel Disease Centers
Shubha Bhat, PharmD, MS, Freddy Caldera, DO, MS, Francis A Farraye, MD, MSc
doi : 10.1093/ibd/izab055
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1356–1357
COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies
Jacqueline D Squire, MD, Alexei Gonzalez-Estrada, MD, Freddy Caldera, DO, MSc, Francis A Farraye, MD, MSc
doi : 10.1093/ibd/izab094
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1358–1360
It Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease
Duke Geem, MD, PhD, Subra Kugathasan, MD
doi : 10.1093/ibd/izaa279
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1361–1362
Maybe Age Isn’t Just a Number: Elderly-onset IBD Is a Demographic Deserving of Specific Considerations
Michael W Winter, MD, L Campbell Levy, MD
doi : 10.1093/ibd/izaa304
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages 1363–1364
Erratum to: Predictors of Perianal Fistula Relapse in Crohn’s Disease
Audrey Malian, MD, Pauline Rivière, MD, Dominique Bouchard, MD, François Pigot, MD, Marianne Eléouet-Kaplan, MD, Charlotte Favreau-Weltzer, MD, Florian Poullenot, MD, David Laharie, MD
doi : 10.1093/ibd/izaa272
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page 1365
Erratum to: Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease
doi : 10.1093/ibd/izab080
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page 1366
Corrigendum to: Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
doi : 10.1093/ibd/izab078
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page 1367
Corrigendum to: Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity
doi : 10.1093/ibd/izab076
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page 1368
Corrigendum to: Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: a Post Hoc Analysis From the CALM Study
doi : 10.1093/ibd/izab079
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page 1369
Safety of Tofacitinib in the COVID-19 Pandemic—Enough Is Not Enough
Philipp A Reuken, PD, MD, Niels Teich, MD, Andreas Stallmach, MD
doi : 10.1093/ibd/izab051
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page e89
The Effect of COVID-19 Resurgence on Morbidity and Mortality in Patients With IBD on Biologic Therapy
Srdjan Markovic, MD, PhD, Tamara Knezevic Ivanovski, MD, Branimir Zogovic, MD, PhD, Ana Kalaba, MD, Dusan Zaric, MD, Petar Svorcan, MD, PhD
doi : 10.1093/ibd/izab048
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page e90
Multiple Nodules in the Kidney and Spleen Presenting as the Initial Manifestation of Crohn Disease
Hikaru Takahashi, MD, Masato Ogawa, MD, PhD, Takayuki Hoshina, MD, PhD, Koichi Kusuhara, MD, PhD
doi : 10.1093/ibd/izab057
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages e91–e92
Dual Targeted Therapy in Patient With Extensive Crohn’s Disease: Different Response at Distinct Location
Giuseppe Privitera, MD, Daniela Pugliese, MD, PhD, Alessandro Armuzzi, MD, PhD, Luisa Guidi, MD, PhD
doi : 10.1093/ibd/izab054
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Pages e93–e94
Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?
Tam?s Res?l, MD, Kata Sz?nt?, MD, Mariann Rutka, MD, PhD, Klaudia Farkas, MD, PhD, Tam?s Moln?r, MD, PhD, Dsc, habil
doi : 10.1093/ibd/izab066
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page e95
Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators
Vipul Jairath, MBChB, DPhil, Leonardo Guizzetti, PhD, K Adam Baker, PhD, Lee Anne Williamson, Rocio Sedano, MD, Hershell Thompson, MSc, MBA, Christopher Ma, MD, MPH
doi : 10.1093/ibd/izab111
Inflammatory Bowel Diseases, Volume 27, Issue 8, August 2021, Page e98
